全文获取类型
收费全文 | 2181篇 |
免费 | 87篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 38篇 |
妇产科学 | 21篇 |
基础医学 | 339篇 |
口腔科学 | 14篇 |
临床医学 | 140篇 |
内科学 | 605篇 |
皮肤病学 | 87篇 |
神经病学 | 184篇 |
特种医学 | 85篇 |
外科学 | 390篇 |
综合类 | 17篇 |
一般理论 | 3篇 |
预防医学 | 122篇 |
眼科学 | 26篇 |
药学 | 94篇 |
肿瘤学 | 86篇 |
出版年
2023年 | 9篇 |
2021年 | 35篇 |
2020年 | 31篇 |
2019年 | 28篇 |
2018年 | 42篇 |
2017年 | 29篇 |
2016年 | 37篇 |
2015年 | 29篇 |
2014年 | 58篇 |
2013年 | 79篇 |
2012年 | 114篇 |
2011年 | 151篇 |
2010年 | 73篇 |
2009年 | 81篇 |
2008年 | 127篇 |
2007年 | 173篇 |
2006年 | 150篇 |
2005年 | 145篇 |
2004年 | 115篇 |
2003年 | 77篇 |
2002年 | 92篇 |
2001年 | 15篇 |
2000年 | 15篇 |
1999年 | 14篇 |
1998年 | 15篇 |
1996年 | 9篇 |
1995年 | 11篇 |
1994年 | 20篇 |
1993年 | 10篇 |
1989年 | 10篇 |
1981年 | 8篇 |
1978年 | 9篇 |
1960年 | 10篇 |
1958年 | 9篇 |
1954年 | 8篇 |
1943年 | 9篇 |
1939年 | 8篇 |
1936年 | 10篇 |
1935年 | 8篇 |
1933年 | 13篇 |
1932年 | 12篇 |
1931年 | 11篇 |
1930年 | 9篇 |
1929年 | 10篇 |
1928年 | 9篇 |
1927年 | 15篇 |
1926年 | 13篇 |
1925年 | 15篇 |
1924年 | 14篇 |
1911年 | 11篇 |
排序方式: 共有2270条查询结果,搜索用时 40 毫秒
1.
2.
Zeitschrift für Psychodrama und Soziometrie - In diesem Beitrag in der Zeitschrift für Psychodrama und Soziometrie wird gezeigt, dass sich grundlegende Bestimmungen des Spiels, die... 相似文献
3.
Comparison of primary percutaneous coronary intervention in patients with ST‐elevation myocardial infarction during and prior to availability of an in‐house STEMI system: Early experience and intermediate outcomes of the HARRT program for achieving routine D2B times <60 minutes 下载免费PDF全文
Ferdinand Leya MD Wojciech Nowak DO PhD Michael Ryan MD Sheldon Freeberg MD Jasrai Gill MD Robert S Dieter MD Lowell Steen MD Bruce Lewis MD Mark Cichon DO Beatrice Probst MD Michael Jarotkiewicz MS David Wilber MD John J. Lopez MD 《Catheterization and cardiovascular interventions》2015,86(2):186-196
4.
Long‐term outcome of belatacept therapy in de novo kidney transplant recipients – a case‐match analysis 下载免费PDF全文
Christoph Schwarz Sophie Mayerhoffer Gabriela A. Berlakovich Rudolf Steininger Thomas Soliman Bruno Watschinger Georg A. Böhmig Farsad Eskandary Franz König Ferdinand Mühlbacher Thomas Wekerle 《Transplant international》2015,28(7):820-827
While belatacept has shown favorable short‐ and midterm results in kidney transplant recipients, only projections exist regarding its potential impact on long‐term outcome. Therefore, we performed a retrospective case‐match analysis of the 14 belatacept patients originally enrolled in the phase II multicenter trial at our center. Fifty six cyclosporine (CyA)‐treated patients were matched according to age at transplantation, first/retransplant, and donor type. Ten years after kidney transplantation, kidney function remained superior in belatacept‐treated patients compared with the CyA control group. Moreover, none of the belatacept‐treated patients had donor‐specific antibodies ≥10 years post‐transplantation compared with 38.5% of tested CyA‐treated subject (0/10 vs. 5/13; P = 0.045). Notably, however, patient and graft survival was virtually identical in both groups (71.4% vs. 71.3%; P = 0.976). In the present single‐center study population, patients treated with belatacept demonstrated a patient and graft survival at 10 years post‐transplant which was comparable to that of similarly selected CNI‐treated patients. Larger studies with sufficient statistical power are necessary to definitively determine long‐term graft survival with belatacept. 相似文献
5.
6.
Jasper Nijkamp Bram Schermers Sander Schmitz Sofieke de Jonge Koert Kuhlmann Ferdinand van der Heijden Jan-Jakob Sonke Theo Ruers 《International journal of computer assisted radiology and surgery》2016,11(8):1487-1498
Purpose
To compare the position and orientation accuracy between using one 6-degree of freedom (DOF) electromagnetic (EM) sensor, or the position information of three 5DOF sensors within the scope of tumor tracking.Methods
The position accuracy of Northern Digital Inc Aurora 5DOF and 6DOF sensors was determined for a table-top field generator (TTFG) up to a distance of 52 cm. For each sensor 716 positions were measured for 10 s at 15 Hz. Orientation accuracy was determined for each of the orthogonal axis at the TTFG distances of 17, 27, 37 and 47 cm. For the 6DOF sensors, orientation was determined for sensors in-line with the orientation axis, and perpendicular. 5DOF orientation accuracy was determined for a theoretical 4 cm tumor. An optical tracking system was used as reference.Results
Position RMSE and jitter were comparable between the sensors and increasing with distance. Jitter was within 0.1 cm SD within 45 cm distance to the TTFG. Position RMSE was approximately 0.1 cm up to 32 cm distance, increasing to 0.4 cm at 52 cm distance. Orientation accuracy of the 6DOF sensor was within 1\(^\circ \), except when the sensor was in-line with the rotation axis perpendicular to the TTFG plane (4\(^\circ \) errors at 47 cm). Orientation accuracy using 5DOF positions was within 1\(^\circ \) up to 37 cm and 2\(^\circ \) at 47 cm.Conclusions
The position and orientation accuracy of a 6DOF sensor was comparable with a sensor configuration consisting of three 5DOF sensors. To achieve tracking accuracy within 1 mm and 1\(^\circ \), the distance to the TTFG should be limited to approximately 30 cm.7.
Dietmar?A.?JacobEmail author Christine?Schug-Pa? Florian?Sommerer Andrea?Tannapfel Hans?Lippert Ferdinand?K?ckerling 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》2012,397(2):283-289
Purpose
The use of a mesh with good biocompatibility properties is of decisive importance for the avoidance of recurrences and chronic pain in endoscopic hernia repair surgery. As we know from numerous experiments and clinical experience, large-pore, lightweight polypropylene meshes possess the best biocompatibility. However, large-pore meshes of different polymers may be used as well and might be an alternative solution. 相似文献8.
Jones PH Hunninghake DB Ferdinand KC Stein EA Gold A Caplan RJ Blasetto JW;Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group 《Clinical therapeutics》2004,26(9):1388-1399
BACKGROUND: Non-high-density lipoprotein cholesterol (HDL-C), apolipoprotein (apo) B, and lipid and apolipoprotein ratios that include both atherogenic and antiatherogenic lipid components have been found to be strong predictors of coronary heart disease risk. OBJECTIVE: The goal of this study was to examine prospectively the effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin across dose ranges on non-HDL-C, apo B, apo A-I, and total cholesterol (TC):HDL-C, low-density lipoprotein cholesterol (LDL-C):HDL-C, non-HDL-C:HDL-C, and apo B:apo A-I ratios in patients with hypercholesterolemia (LDL-C > or =160 mg/dL and <250 mg/dL and triglycerides <400 mg/dL) in the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial. METHODS: In this randomized, Multicenter, parallel-group, open-label trial (4522IL/0065), patients > or =18 years of age received rosuvastatin 10, 20, 40, or 80 mg; atorvastatin 10, 20, 40, or 80 mg; simvastatin 10, 20, 40, or 80 mg; or pravastatin 10, 20, or 40 mg for 6 weeks. Pairwise comparisons were prospectively planned and performed between rosuvastatin 10, 20, and 40 mg and milligram-equivalent or higher doses of comparators. RESULTS: A total of 2268 patients were randomized to the rosuvastatin 10- to 40-mg, atorvastatin, simvastatin, and pravastatin groups. Fifty-one percent of patients were women, the mean (SD) age was 57 (12) years, and 19% had a documented history of atherosclerotic disease. Over 6 weeks, rosuvastatin significantly reduced non-HDL-C, apo B, and all lipid and apolipoprotein ratios assessed, compared with milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin (all, P < 0.002). Rosuvastatin reduced non-HDL-C by 42.0% to 50.9% compared with 34.4% to 48.1% with atorvastatin, 26.0% to 41.8% with simvastatin, and 18.6% to 27.4% with pravastatin. Rosuvastatin reduced apo B by 36.7% to 45.3% compared with 29.4% to 42.9% with atorvastatin, 22.2% to 34.7% with simvastatin, and 14.7% to 23.0% with pravastatin. The highest increase in apo A-I (8.8%) was observed in the rosuvastatin 20-mg group, and this increase was significantly greater than in the atorvastatin 40-mg and 80-mg groups (both, P < 0.002). CONCLUSION: Rosuvastatin 10 to 40 mg was more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin. 相似文献
9.
10.
The Location of Pretreatment Hyperdense Middle Cerebral Artery Sign Predicts the Outcome of Intraarterial Thrombectomy for Acute Stroke 下载免费PDF全文